CN118076604A - 用于治疗自身免疫性疾病的吡唑并[3,4-b]吡啶化合物 - Google Patents

用于治疗自身免疫性疾病的吡唑并[3,4-b]吡啶化合物 Download PDF

Info

Publication number
CN118076604A
CN118076604A CN202280063841.XA CN202280063841A CN118076604A CN 118076604 A CN118076604 A CN 118076604A CN 202280063841 A CN202280063841 A CN 202280063841A CN 118076604 A CN118076604 A CN 118076604A
Authority
CN
China
Prior art keywords
methyl
piperidinyl
pyridinyl
compound
pyridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280063841.XA
Other languages
English (en)
Chinese (zh)
Inventor
陈冬冬
F·戴伊
洪鑫
王晓卿
张志森
朱伟
邹舸
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN118076604A publication Critical patent/CN118076604A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202280063841.XA 2021-09-24 2022-09-22 用于治疗自身免疫性疾病的吡唑并[3,4-b]吡啶化合物 Pending CN118076604A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2021120406 2021-09-24
CNPCT/CN2021/120406 2021-09-24
CN2022089033 2022-04-25
CNPCT/CN2022/089033 2022-04-25
PCT/EP2022/076306 WO2023046806A1 (en) 2021-09-24 2022-09-22 Pyrazolo[3,4-b]pyridine compounds for the treatment of autoimmune disease

Publications (1)

Publication Number Publication Date
CN118076604A true CN118076604A (zh) 2024-05-24

Family

ID=83688579

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280063841.XA Pending CN118076604A (zh) 2021-09-24 2022-09-22 用于治疗自身免疫性疾病的吡唑并[3,4-b]吡啶化合物

Country Status (16)

Country Link
US (1) US20240360126A1 (enExample)
EP (1) EP4405051A1 (enExample)
JP (1) JP2024534567A (enExample)
KR (1) KR20240065092A (enExample)
CN (1) CN118076604A (enExample)
AR (1) AR127126A1 (enExample)
AU (1) AU2022351495A1 (enExample)
CA (1) CA3228485A1 (enExample)
CL (1) CL2024000791A1 (enExample)
CO (1) CO2024003401A2 (enExample)
CR (1) CR20240134A (enExample)
IL (1) IL310443A (enExample)
MX (1) MX2024003444A (enExample)
PE (2) PE20240815A1 (enExample)
TW (1) TW202328129A (enExample)
WO (1) WO2023046806A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024222889A1 (zh) * 2023-04-28 2024-10-31 成都思倍博医药科技有限公司 含氧代吡啶并脂肪环或脂杂环结构的化合物及其医药用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3080124A1 (en) * 2013-12-13 2016-10-19 Takeda Pharmaceutical Company Limited Pyrrolo[3,2-c]pyridine derivatives as tlr inhibitors
CR20190119A (es) 2016-09-09 2019-06-03 Novartis Ag Compuestos y composiciones como inhibidores de los receptores endosomales tipo peaje
JP7407740B2 (ja) 2018-05-18 2024-01-04 ノバルティス アーゲー Ｔｌｒ７／ｔｌｒ８阻害剤の結晶形態
WO2022013136A1 (en) * 2020-07-14 2022-01-20 F. Hoffmann-La Roche Ag Hydroisoquinoline or hydronaphthyridine compounds for the treatment of autoimmune disease

Also Published As

Publication number Publication date
US20240360126A1 (en) 2024-10-31
CL2024000791A1 (es) 2024-09-06
AU2022351495A1 (en) 2024-02-01
EP4405051A1 (en) 2024-07-31
IL310443A (en) 2024-03-01
WO2023046806A1 (en) 2023-03-30
MX2024003444A (es) 2024-04-03
PE20250401A1 (es) 2025-02-11
AR127126A1 (es) 2023-12-20
CR20240134A (es) 2024-05-07
JP2024534567A (ja) 2024-09-20
CA3228485A1 (en) 2023-03-30
CO2024003401A2 (es) 2024-04-29
PE20240815A1 (es) 2024-04-18
KR20240065092A (ko) 2024-05-14
TW202328129A (zh) 2023-07-16

Similar Documents

Publication Publication Date Title
KR101823488B1 (ko) 선택적으로 치환된 퀴놀린 화합물
TW202413351A (zh) 藉由irak4抑制劑與e3連接酶配體的軛合降解irak4及使用方法
CN113710672B (zh) 用于治疗自身免疫性疾病的六氢-1H-吡嗪并[1,2-a]吡嗪化合物
WO2019238629A1 (en) Pyridinyl heterocyclyl compounds for the treatment of autoimmune disease
CA3098291A1 (en) Tetrahydro-1 h-pyrazino[2,1 -ajisoindolylquinoline compounds for the treatment of autoimmune disease
TW202024065A (zh) 用於治療自體免疫疾病之雜環基化合物
CN112584903A (zh) 用于自身免疫性疾病治疗的新型哌嗪化合物
JP2024543377A (ja) 造血前駆体キナーゼの二官能性分解物質およびその治療的使用
JP2023533807A (ja) 自己免疫疾患の処置のためのヒドロイソキノリン又はヒドロナフチリジン化合物
CN114599652B (zh) 用于治疗自身免疫性疾病的氢吡嗪并[1,2-d][1,4]二氮杂䓬化合物
CN118076604A (zh) 用于治疗自身免疫性疾病的吡唑并[3,4-b]吡啶化合物
CN114728987A (zh) 用于治疗自身免疫性疾病的1,8-萘啶-2-酮化合物
EA052162B1 (ru) СОЕДИНЕНИЯ ПИРАЗОЛО[3,4-b]ПИРИДИНА ДЛЯ ЛЕЧЕНИЯ АУТОИММУННОГО ЗАБОЛЕВАНИЯ
CN115835911A (zh) 用于治疗自身免疫性疾病的咪唑并[1,2-a]吡啶化合物
HK40107666A (zh) 用於治疗自身免疫性疾病的吡唑并[3，4-b]吡啶化合物
HK40071770A (en) 1,8-naphthyridin-2-one compounds for the treatment of autoimmune disease
HK40086354A (zh) 用於治疗自身免疫性疾病的氢化异喹啉或氢化萘啶化合物
HK40055574B (zh) 用於治疗自身免疫性疾病的六氢-1h-吡嗪幷[1，2- a]吡嗪化合物
HK40055574A (en) Hexahydro-1h-pyrazino[1,2-a]pyrazine compounds for the treatment of autoimmune disease
HK40071770B (zh) 用於治疗自身免疫性疾病的1， 8-萘啶-2-酮化合物
HK1223092B (en) Selectively substituted quinoline compounds

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40107666

Country of ref document: HK